Literature DB >> 32386722

The HIV-1 antibody response: a footprint of the viral reservoir in children vertically infected with HIV.

Paolo Palma1, Margaret McManus2, Nicola Cotugno3, Salvatore Rocca4, Paolo Rossi3, Katherine Luzuriaga5.   

Abstract

Several assays have been developed to measure and characterise the replication-competent HIV-1 reservoir, which constitutes the barrier to cure. To date, the application of these assays to studies in children and in limited-resource settings has been minimal, primarily because of their expense, the large required blood volumes, and labour-intensive technologies. For children vertically infected with HIV-1 who initiated suppressive antiretroviral therapy (ART) regimens in infancy, HIV-1-specific antibody concentrations are associated with viral persistence and could be used to estimate the size of the residual latent reservoir on ART. This strategy could be particularly useful for screening children on suppressive ART for enrolment into therapeutic vaccine trials and other protocols aimed at achieving HIV-1 remission.
Copyright © 2020 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 32386722      PMCID: PMC7593885          DOI: 10.1016/S2352-3018(20)30100-4

Source DB:  PubMed          Journal:  Lancet HIV        ISSN: 2352-3018            Impact factor:   12.767


  58 in total

1.  A stable latent reservoir for HIV-1 in resting CD4(+) T lymphocytes in infected children.

Authors:  D Persaud; T Pierson; C Ruff; D Finzi; K R Chadwick; J B Margolick; A Ruff; N Hutton; S Ray; R F Siliciano
Journal:  J Clin Invest       Date:  2000-04       Impact factor: 14.808

2.  Young age at start of antiretroviral therapy and negative HIV antibody results in HIV-infected children when suppressed.

Authors:  Louise Kuhn; Diana B Schramm; Stephanie Shiau; Renate Strehlau; Francoise Pinillos; Karl Technau; Ashraf Coovadia; Elaine J Abrams; Adrian Puren; Caroline T Tiemessen
Journal:  AIDS       Date:  2015-06-01       Impact factor: 4.177

3.  Cell-Associated HIV-1 DNA and RNA Decay Dynamics During Early Combination Antiretroviral Therapy in HIV-1-Infected Infants.

Authors:  Priyanka Uprety; Ellen G Chadwick; Kaitlin Rainwater-Lovett; Carrie Ziemniak; Katherine Luzuriaga; Edmund V Capparelli; Gayane Yenokyan; Deborah Persaud
Journal:  Clin Infect Dis       Date:  2015-08-13       Impact factor: 9.079

4.  Intact HIV-1 proviruses accumulate at distinct chromosomal positions during prolonged antiretroviral therapy.

Authors:  Kevin B Einkauf; Guinevere Q Lee; Ce Gao; Radwa Sharaf; Xiaoming Sun; Stephane Hua; Samantha My Chen; Chenyang Jiang; Xiaodong Lian; Fatema Z Chowdhury; Eric S Rosenberg; Tae-Wook Chun; Jonathan Z Li; Xu G Yu; Mathias Lichterfeld
Journal:  J Clin Invest       Date:  2019-01-28       Impact factor: 14.808

5.  Viremic relapse after HIV-1 remission in a perinatally infected child.

Authors:  Katherine Luzuriaga; Hannah Gay; Carrie Ziemniak; Keri B Sanborn; Mohan Somasundaran; Kaitlin Rainwater-Lovett; John W Mellors; Daniel Rosenbloom; Deborah Persaud
Journal:  N Engl J Med       Date:  2015-02-19       Impact factor: 91.245

6.  Early therapy in HIV-1-infected children: effect on HIV-1 dynamics and HIV-1-specific immune response.

Authors:  Marisa Zanchetta; Alessia Anselmi; Daniela Vendrame; Osvalda Rampon; Carlo Giaquinto; Antonio Mazza; Daniele Accapezzato; Vincenzo Barnaba; Anita De Rossi
Journal:  Antivir Ther       Date:  2008

Review 7.  Paediatric HIV infection: the potential for cure.

Authors:  Philip J Goulder; Sharon R Lewin; Ellen M Leitman
Journal:  Nat Rev Immunol       Date:  2016-03-14       Impact factor: 53.106

8.  HIV Antibody Level as a Marker of HIV Persistence and Low-Level Viral Replication.

Authors:  Sheila M Keating; Christopher D Pilcher; Vivek Jain; Mila Lebedeva; Dylan Hampton; Mohamed Abdel-Mohsen; Xutao Deng; Gary Murphy; Alex Welte; Shelley N Facente; Frederick Hecht; Steven G Deeks; Satish K Pillai; Michael P Busch
Journal:  J Infect Dis       Date:  2017-07-01       Impact factor: 5.226

9.  Estimating the cost of diagnosing HIV at birth in Lesotho.

Authors:  M Tchuenche; M M Gill; L Bollinger; L Mofenson; M Phalatse; M Nchephe; M Mokone; V Tukei; A Tiam; S Forsythe
Journal:  PLoS One       Date:  2018-08-15       Impact factor: 3.240

10.  Paediatric European Network for Treatment of AIDS Treatment Guideline 2016 update: antiretroviral therapy recommended for all children living with HIV.

Authors:  C Foster; A Bamford; A Turkova; S Welch; N Klein
Journal:  HIV Med       Date:  2016-07-06       Impact factor: 3.180

View more
  7 in total

1.  Clinical, Virological and Immunological Subphenotypes in a Cohort of Early Treated HIV-Infected Children.

Authors:  Sara Domínguez-Rodríguez; Alfredo Tagarro; Caroline Foster; Paolo Palma; Nicola Cotugno; Sonia Zicari; Alessandra Ruggiero; Anita de Rossi; Annalisa Dalzini; Savita Pahwa; Stefano Rinaldi; Eleni Nastouli; Anne-Geneviève Marcelin; Karim Dorgham; Delphine Sauce; Kathleen Gartner; Paolo Rossi; Carlo Giaquinto; Pablo Rojo
Journal:  Front Immunol       Date:  2022-05-03       Impact factor: 8.786

2.  Clinical validation of a quantitative HIV-1 DNA droplet digital PCR assay: Applications for detecting occult HIV-1 infection and monitoring cell-associated HIV-1 dynamics across different subtypes in HIV-1 prevention and cure trials.

Authors:  Laura Powell; Adit Dhummakupt; Lilly Siems; Dolly Singh; Yann Le Duff; Priyanka Uprety; Cheryl Jennings; Joseph Szewczyk; Ya Chen; Eleni Nastouli; Deborah Persaud
Journal:  J Clin Virol       Date:  2021-04-14       Impact factor: 14.481

Review 3.  Understanding Viral and Immune Interplay During Vertical Transmission of HIV: Implications for Cure.

Authors:  Omayma Amin; Jenna Powers; Katherine M Bricker; Ann Chahroudi
Journal:  Front Immunol       Date:  2021-10-21       Impact factor: 7.561

4.  Viral suppression is associated with HIV-antibody level and HIV-1 DNA detectability in early treated children at 2 years of age.

Authors:  Kirsten A Veldsman; Barbara Laughton; Anita Janse van Rensburg; Peter Zuidewind; Els Dobbels; Shaun Barnabas; Samantha Fry; Mark F Cotton; Gert U van Zyl
Journal:  AIDS       Date:  2021-07-01       Impact factor: 4.632

5.  Impact of HIV-1 Vpr manipulation of the DNA repair enzyme UNG2 on B lymphocyte class switch recombination.

Authors:  Patrick Eldin; Sophie Péron; Anastasia Galashevskaya; Nicolas Denis-Lagache; Michel Cogné; Geir Slupphaug; Laurence Briant
Journal:  J Transl Med       Date:  2020-08-10       Impact factor: 5.531

Review 6.  Residual Proviral Reservoirs: A High Risk for HIV Persistence and Driving Forces for Viral Rebound after Analytical Treatment Interruption.

Authors:  Xiaolei Wang; Huanbin Xu
Journal:  Viruses       Date:  2021-02-21       Impact factor: 5.048

7.  Early ART-initiation and longer ART duration reduces HIV-1 proviral DNA levels in children from the CHER trial.

Authors:  Helen Payne; Man K Chan; Sarah A Watters; Kennedy Otwombe; Nei-Yuan Hsiao; Abdel Babiker; Avy Violari; Mark F Cotton; Diana M Gibb; Nigel J Klein
Journal:  AIDS Res Ther       Date:  2021-09-29       Impact factor: 2.250

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.